A Study to Test How Well BI 3720931 is Tolerated and Whether it Improves Lung Function in People With Cystic Fibrosis (Lenticlair™ 1)

NCT06515002 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Cystic Fibrosis

Interventions

GENETIC: BI 3720931
DRUG: Placebo
DEVICE: Inhaler

Sponsor

Boehringer Ingelheim